Immune begins patient enrollment in Phase II trial to treat ulcerative colitis

US-based Immune Pharmaceuticals has begun enrolling patients in a Phase II clinical trial of bertilimumab, a potential treatment for ulcerative colitis (UC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news